SEER · Seer, Inc.
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|---|
| $16M – $18M | $14.22M | $16.58M | $14.17MG | $16.66M | $15.49M | $6.62M | $656K | |
| — | — | — | — | $100K | — | — | — | |
| — | $7.44M | $8.11M | $7.12M | $8.16M | $8.4M | $3.21M | $0 | |
| — | $6.78M | $8.47M | $7.06M | $8.51M | $7.09M | $3.41M | $656K | |
| — | — | 51.06% | 49.79% | 51.05% | 45.78% | 51.56% | 100% | |
| — | $37.55M | $43.87M | $50.59M | $53.02M | $45.8M | $29.12M | $18.94M | |
| — | $40.06M | $42.58M | $56.57M | $58.95M | $58.53M | $45.76M | $15.36M | |
| — | $4.65M | $5.12M | $5.84M | $5.35M | — | — | — | |
| — | $77.61M | $86.46M | $107.16M | $111.97M | $104.33M | $74.89M | $34.31M | |
| — | -$70.83M | -$77.99M | -$100.1M | -$103.46M | -$97.24M | -$71.47M | -$33.65M | |
| — | — | -470.45% | -706.43% | -620.99% | -627.61% | -1080.14% | -5129.42% | |
| — | -$66.18M | -$72.87M | -$94.27M | -$98.11M | — | — | — | |
| — | — | — | — | — | $0 | $22K | $0 | |
| — | $9.59M | $11.52M | $16.67M | $17.76M | $4.6M | $326K | $883K | |
| — | $2.94M | $4.59M | $13.6M | $17.19M | $4.27M | $304K | $874K | |
| — | -$6.32M | -$5.92M | -$2.65M | $0 | — | — | — | |
| — | -$67.89M | -$73.4M | -$86.5M | -$86.28M | — | — | — | |
| — | $71K | $201K | $98K | $0 | $0 | $0 | $0 | |
| — | -$67.96M | -$73.6M | -$86.6M | -$86.28M | -$92.97M | -$71.17M | -$32.78M | |
| — | — | -443.96% | -611.14% | -517.84% | -600.05% | -1075.55% | -4996.19% | |
| — | — | — | — | — | — | -$71.17M | -$32.78M | |
| — | -$68.61M | -$73.28M | -$86.27M | -$85.22M | -$93.68M | -$71.76M | -$32.75M | |
| USD/shares | — | — | — | — | -$1.35 | -$1.49 | -$1.17 | -$2.48 |
| USD/shares | — | — | — | — | -$1.35 | -$1.49 | -$1.17 | -$2.48 |
| shares | — | — | — | — | 63.85M | 62.43M | 60.86M | 13.22M |
| shares | — | — | — | — | 63.85M | 62.43M | 60.86M | 13.22M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2020–FY2024: $81K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 305 similar-size Biotechnology companies (of 545 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Product | $8,557,000 | $3,577,000 | $0 |
| Related Party | $5,215,000 | $2,317,000 | $0 |
| Service | $913,000 | $500,000 | $0 |
| Grant and Other | $808,000 | $223,000 | — |
| Grant | — | — | $656,000 |